Condition: HDV · Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special population is unmet need. Therefore, this study plans to perform a nationwide survey of the prevalence and predictor of HDV among people uses drugs (PWID) with and without HIV, HBV/HIV (MSM vs non MSM), HBV related cirrhosis. Findinds from this study will provide the scientific community to understand how important HDV is among HBV patients, this could be used to develop strategies for HDV screening and treatment
This description comes directly from the study's public registry record.
Chatsuda Auchieng · 6626523040 · chatsuda.a@hivnat.org
Pirapon J Ohata, BSc · 6626523040 · juneohata4@gmail.com
Always discuss trial participation with your own doctor first.
| HIV-NAT, Thai Red Cross - AIDS Research Centre | Bangkok, Bangkok, Thailand | Recruiting |
| King memorial Chulalongkorn hospital | Bangkok, Bangkok, Thailand | Recruiting |
| Siriraj Hospital, Mahidol University | Bangkok, Bangkok, Thailand | Recruiting |
| Taksin Hospital | Bangkok, Bangkok, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05350865